Gastroenteropancreatic neuroendocrine tumors
RayzeBio Inc. focuses its clinical research on gastroenteropancreatic neuroendocrine tumors, with attention to advanced, inoperable disease and tumors expressing somatostatin receptors. The company’s current trial activity centers on patients whose disease has progressed after prior 177Lu-labeled somatostatin analogue therapy.
- SSTR-positive GEP-NETs
- Advanced well-differentiated neuroendocrine tumors
- Post-177Lu-SSA disease progression
The research program is directed toward treatment options for patients with limited local therapeutic choices in metastatic and unresectable neuroendocrine neoplasms.
Targeted radiopharmaceutical therapy
The sponsor’s trial portfolio includes investigation of RYZ101, a targeted therapeutic approach designed for receptor-expressing tumors. This places emphasis on radioligand-based oncology and selective delivery to somatostatin receptor-positive cancer cells.
- RYZ101
- Radiopharmaceutical oncology
- Somatostatin receptor targeting
Clinical interest extends to therapies intended to address progression after prior radionuclide treatment in neuroendocrine tumor populations.
Safety and tolerability in oncology
RayzeBio’s research activities include evaluation of safety and tolerability in patients with advanced GEP-NETs. The clinical focus reflects interest in defining how targeted treatment is received in a population with prior exposure to somatostatin analogue therapy.
- Oncology safety assessment
- Tolerability in advanced disease
- Previously treated neuroendocrine tumors
This area of work is centered on patients with progressive disease requiring additional systemic treatment options.
Progression-free survival in advanced disease
The company’s trial objectives also include assessment of progression-free survival in centrally confirmed disease, underscoring interest in outcomes for patients with advanced somatostatin receptor-expressing tumors. This clinical domain is closely tied to treatment benefit in unresectable neuroendocrine cancer.
- Progression-free survival
- Central disease confirmation
- Unresectable neuroendocrine cancer
The therapeutic emphasis remains on disease control in a refractory GEP-NET setting.
